KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Inventory (2016 - 2025)

Sarepta Therapeutics (SRPT) has 10 years of Inventory data on record, last reported at $1.1 billion in Q3 2025.

  • For Q3 2025, Inventory changed N/A year-over-year to $1.1 billion; the TTM value through Sep 2025 reached $1.1 billion, changed N/A, while the annual FY2024 figure was $750.0 million, 132.29% up from the prior year.
  • Inventory reached $1.1 billion in Q3 2025 per SRPT's latest filing, up from $994.0 million in the prior quarter.
  • Across five years, Inventory topped out at $1.1 billion in Q3 2025 and bottomed at $186.2 million in Q4 2021.
  • Average Inventory over 5 years is $458.1 million, with a median of $278.6 million recorded in 2021.
  • Peak YoY movement for Inventory: fell 22.57% in 2022, then soared 132.29% in 2024.
  • A 5-year view of Inventory shows it stood at $186.2 million in 2021, then rose by 9.54% to $204.0 million in 2022, then surged by 58.29% to $322.9 million in 2023, then skyrocketed by 132.29% to $750.0 million in 2024, then skyrocketed by 43.63% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $1.1 billion in Q3 2025, $994.0 million in Q2 2025, and $941.4 million in Q1 2025.